June 9, 2011
ImmunoCellular Therapeutics (IMUC.OB) expands P2 Trial of ICT-107
May 28, 2011
Regenerative Medicine Weekly Trend Line
May 27, 2011
The RegMed Daily Dialogue, 5/27/11, wish I wasn't here
May 25, 2011
The RegMed Daily Dialogue, 5/25/11, the trend is not your friend ...yet
May 24, 2011
ImmunoCellular Therapeutics (IMUC.OB) New Data from PI Glioblastoma Multiforme Trial at ASCO
May 19, 2011
StemCells (STEM) new Proxy to affect a Reverse Stock Split
May 17, 2011
NeoStem (AMEX: NBS) Q1/11 Results
May 16, 2011
Aastrom Biosciences (ASTM) Q1/11 Results
May 16, 2011
The RegMed Daily Dialogue, Monday, 5/16/11, Navigating the soft patch
May 5, 2011
The Daily Dialogue, Mid-day, Thursday, 5/5/11
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.